IMC:ASX
Immuron Ltd
A$0.040
0.00%
(0.00) 1D
Oct 29, 3:12:42 PM GMT+11 · AUD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for IMC...
Mkt. cap
12.91M
Avg. vol.
170.90K
Volume
0.00
52-wk high
A$0.10
52-wk low
A$0.03
EPS
-A$0.01
Shares outstanding
322.85M
No. of employees
8
Mkt. cap
12.91M
Avg. vol.
170.90K
Volume
0.00
52-wk high
A$0.10
52-wk low
A$0.03
EPS
-A$0.01
Shares outstanding
322.85M
No. of employees
8
News stories
From web sources and news partners
FinancialContent
·
1 hour ago
Chegg’s (NYSE:CHGG) Q3 2026: beats on revenue but quarterly revenue guidance slightly misses expectations
PR Newswire Canada
·
23 minutes ago
NYSE-Affiliated Venue for Tokenization Adds Transfer Agents: NYSE Content Update
Barchart.com
·
1 hour ago
Upstart (NASDAQ:UPST) posts better-than-expected sales in Q3 2026, stock soars
Seeking Alpha
·
32 minutes ago
It's Time To Go All-In On Stocks (SP500)
Profile
Immuron is a biotechnology company based in Melbourne, Australia. In 2008, the company changed its name to Immuron Limited, having previously operated as Anadis Limited.
Immuron is focused on antigen-primed and dairy-derived health products. Its proprietary technologies allow for rapid development of polyclonal antibody and other proteins-based solutions for a range of diseases. The company specialises in nutraceutical, pharmaceutical and therapeutic technology products for conditions such as oral and GI mucositis, avian influenza, E. coli travellers' diarrhoea and Anthrax containment.
In 2005, Anadis signed an agreement with Quebec's Baralex Inc. and Valeo Pharma Inc. for the distribution of Travelan, a product made by Anadis for the Canadian market. Wikipedia
About Immuron Ltd
CEO-
Employees8
Founded1994
HeadquartersBlackburn North, Victoria, Australia
SectorBiotechnology
Websiteimmuron.com.au